RXRX - Recursion Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RXRX is currently covered by 7 analysts with an average price target of $10.81. This is a potential upside of $5.31 (96.55%) from yesterday's end of day stock price of $5.5.

Recursion Pharmaceuticals's activity chart (see below) currently has 21 price targets and 48 ratings on display. The stock rating distribution of RXRX is 82.76% BUY and 17.24% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 63.82% with an average time for these price targets to be met of 55.25 days.

Highest price target for RXRX is $11, Lowest price target is $8, average price target is $13.33.

Most recent stock forecast was given by VIKRAM PUROHIT from MORGAN STANLEY on 10-Apr-2025. First documented stock forecast 11-May-2021.

Currently out of the existing stock ratings of RXRX, 24 are a BUY (82.76%), 5 are a HOLD (17.24%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$8

$2.24 (38.89%)

$10

8 days ago
(10-Apr-2025)

2/3 (66.67%)

$3.49 (77.38%)

96

Buy

$11

$5.24 (90.97%)

$11

10 days ago
(08-Apr-2025)

2/19 (10.53%)

$7.03 (177.08%)

71

Buy

$10

$4.24 (73.61%)

$12

3 months 10 days ago
(08-Jan-2025)

3/6 (50%)

$2.74 (37.74%)

36

Hold

$8

$2.24 (38.89%)

$8

7 months 15 days ago
(03-Sep-2024)

5/6 (83.33%)

$1.93 (31.80%)

69

Hold

$10

$4.24 (73.61%)

$32

1 years 5 months 5 days ago
(13-Nov-2023)

2/2 (100%)

$4.17 (71.53%)

35

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RXRX (Recursion Pharmaceuticals) average time for price targets to be met?

On average it took 55.25 days on average for the stock forecasts to be realized with a an average price target met ratio 63.82

Which analyst has the current highest performing score on RXRX (Recursion Pharmaceuticals) with a proven track record?

GIL BLUM

Which analyst has the current lower performing score on RXRX (Recursion Pharmaceuticals) with a proven track record?

VIKRAM PUROHIT

Which analyst has the most public recommendations on RXRX (Recursion Pharmaceuticals)?

Gil Blum works at NEEDHAM and has 24 price targets and 21 ratings on RXRX

Which analyst is the currently most bullish on RXRX (Recursion Pharmaceuticals)?

Gal Munda with highest potential upside - $27.24

Which analyst is the currently most reserved on RXRX (Recursion Pharmaceuticals)?

Michael Ryskin with lowest potential downside - -$0.53

Recursion Pharmaceuticals in the News

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small...

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?